Looking for day and swing momentum alerts? LionStockAlerts has you covered. They call it like it is cutting through the BS to deliver real alerts
Impax is a generic mfg with a proprietary arm that is super successful, Rytary, 88% margins and just ramping heading to $350-400 mill annual. Co has more cash than debt and big prospects with huge approvals coming. Already got Adderal XR awaiting Renvela and Official launch of generic Oxycontin. Throwing off $80 million in free cash per qaurter and just starting to ramp!! It's coming watch for it!!
Hard to imagine that ANAC continues to trade above $99. The deal does not close until Q3,the arbs who will be the holders at the closing date will want something like a 7% to 10% return so this will trade at arrund 97 by end of day and around 91 by week's end. Watch your purchase price!
This stock reached $156 and stayed in the 145-155 zone a number of days and the CEO sells out at $98 in the pre-market. Not much confidence in the Biotech world.
This is proof that the Market is headed much lower.
Kerydin, for toenail fungus yikes. Too many drugs already on market for that. Psoriasis drugs. Somedays I wonder who works for these big pharma companies to the point of who makes these odd decisions to purchase a company. Oh well congrats to those who held ANAC.
Doesn't sound like promoting Kerydin when it says "launch new product"
The District Manager (DM) who wins this position will:
Hire, train, coach, and inspire 9-11 Dermatology or Pediatric/Primary Care sale representatives
Successfully launch Anacor's new product and grow with Anacor as the company's portfolio expands
Direct the district's actions and activities, while identifying and taking action on growth opportunities
Meet or exceed all assigned sales objectives
Perms his/her duties in a highly ethical manner in accordance with applicable law, best practices, and the company's healthcare compliance policies
It's the investor that needs to wake up. They sport a negative EPS which means they are not making money. That showed up on their last earnings report plus Ippolito is given shares and selling the same day for a million and a half dollars profit (insider info Jan. 19th). A repeat performance in Feb. and Mar. gave him even more money. I have no problem with bonus money for performance but milking the company on the backs of shareholders is way out there.